ID   LL1
AC   CVCL_C4MN
SY   EPB-1; EPB1
DR   ABCD; ABCD_AD421
DR   Wikidata; Q116049709
RX   PubMed=2663143;
RX   PubMed=8947500;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized milatuzumab (hLL1; MEDI-115) therapeutic antibody used for the treatment of multiple myeloma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. When conjugated with doxorubicin, milatuzumab is known as IMMU-110 (hLL1-Dox) and is used for the treatment of relapsed multiple myeloma.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P04233; Human CD74.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   PubMed=2663143;
RA   Pawlak-Byczkowska E.J., Hansen H.J., Dion A.S., Goldenberg D.M.;
RT   "Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human
RT   lymphoma.";
RL   Cancer Res. 49:4568-4577(1989).
//
RX   PubMed=8947500; DOI=10.1042/bj3200293;
RA   Hansen H.J., Ong G.L., Diril H., Valdez A., Roche P.A.,
RA   Griffiths G.L., Goldenberg D.M., Mattes M.J.;
RT   "Internalization and catabolism of radiolabelled antibodies to the MHC
RT   class-II invariant chain by B-cell lymphomas.";
RL   Biochem. J. 320:293-300(1996).
//